Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509860 · ClinicalTrials.gov registry record · Phase 2
Irinotecan (Camptosar) in Patients With Advanced Sarcomas
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00509860: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00509860 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00509860, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
Primary Objectives: 1. To determine the efficacy of the topoisomerase I (topo I) inhibitor irinotecan, delivered via a low-dose protracted schedule to patients with advanced sarcoma. 2. To determine the toxicity profile of irinotecan, using a protracted schedule, in this pretreated patient population.
Interventions
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2003-03 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509860
The ClinicalTrials.gov registry entry for NCT00509860 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Irinotecan is the first listed.
NCT00509860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509860 about?
NCT00509860 is a clinical study titled "Irinotecan (Camptosar) in Patients With Advanced Sarcomas". Primary Objectives: 1. To determine the efficacy of the topoisomerase I (topo I) inhibitor irinotecan, delivered via a low-dose protracted schedule to patients with advanced sarcoma. 2. To determine the toxicity profile of irinotecan, using a protracted schedule, in this pretreated patient populati...
What is the current status of trial NCT00509860?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2003-03. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00509860?
The interventions under investigation include: Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00509860?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.